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Abstract: 
 
Background: Male circumcision(MC) can reduce HIV acquisition. However, a better 
understanding of the indirect protective effect of MC on sexually transmitted infections 
(STIs) is required. 
Objective: To assess the incremental benefits conferred by MC on HIV infection at the 
individual-level in circumcision trials (no herd immunity effect) and at the population-
level (with herd immunity effect) due to its protective effect against other STIs.  
Methods: A dynamical stochastic model of HIV and STI infections in a Kenyan 
population was used to simulate the impact of circumcision offered to a minority of trials 
participants or to a large fraction of men in order to study the protective role of MC on 
HIV infection at the individual-level and at the population-level, respectively.  
Results: Less than 20% of the HIV infections prevented in the circumcised arm of the 
circumcision trials (individual-level) could be attributable to MC efficacy against STIs 
rather than MC efficacy against HIV. At the population-level, MC can significantly 
reduce HIV prevalence especially among males and among females in the longer term. 
However, even at the population-level, the long-term incremental impact of MC on HIV 
due to the protection against STI is modest (even if MC efficacy against the STI and STI 
prevalence was high).  
Discussion: The protection of MC against STI contributes little to the overall effect of 
MC on HIV in the trials. Additional work is needed to identify if the protective effect of 
MC efficacy against STIs can have a significant incremental benefit on the HIV 
epidemic.  
 
(wc 243)
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List of abbreviations 
UNIM = Universities of Nairobi, Illinois and Manitoba 
MC = Male circumcision 
RCT = randomised control trial 
ES
HIV
 = Efficacy due to a reduction in susceptibility to HIV infection 
ES
STI
 = Efficacy due to a reduction in susceptibility to STI infection 
EI
HIV
= Efficacy due to a reduction in HIV infectiousness of HIV positive circumcised 
men
 
EI
STI
= Efficacy due to a reduction in STI infectiousness of STI positive circumcised men
 
Enh
STI
 =Efficacy due to a change in the STI natural history among circumcised men
 
GUD= Genital ulcer diseases 
RRs= Relative risk of HIV due to STI 
 
 
Word count= 3270 
 4 
The Corresponding Author has the right to grant on behalf of all authors and 
does grant on behalf of all authors, an exclusive licence (or non exclusive 
for government employees) on a worldwide basis to the BMJ Publishing Group Ltd  
to permit this article (if accepted) to be published in STI and any other 
BMJPGL products and sub-licences such use and exploit all subsidiary rights, 
as set out in our licence http://sti.bmjjournals.com/ifora/licence.pdf)". If 
your manuscript does not contain this statement, you will be contacted by the 
Editorial staff to ensure that it is added. 
 
Authors’ contribution: 
All authors have contributed to the planning, the interpretation of the results and the 
redaction of the manuscript. In addition, MCB and KD have performed written he first 
version of the manuscript, designed the study and performed the analysis.  
 5 
Key Messages: 
 
 It is important to distinguish between the overall effectiveness of MC and the 
efficacies of male circumcision (MC) against HIV and STIs in order to assess the 
population-level impact of MC on HIV 
 Only a small fraction of the observed MC effectiveness against HIV in the three 
MC RCT could be due to the indirect efficacy against STIs, rather than the direct 
efficacy against HIV 
 The direct protection of MC against HIV has the potential to help curb the HIV 
epidemic, in the long term, in population where MC prevalence is low and in 
absence of associated sexual disinhibition. If enough men are circumcised, 
females will benefit from long-term herd immunity effects. 
 However, the incremental population-level benefit of MC on HIV due to a 
reduction in the acquisition of STIs(Es
STI
) among male is predicted to be modest 
in mature HIV epidemics, unless MC efficacy against STI is very high.  
 More research is needed to better understand the potential protective mechanisms 
of MC against STI at both the individual and population-level. 
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Introduction 
 
There is compelling evidence that male circumcision(MC) reduces susceptibility to HIV 
infection. Early evidence was based on ecological and observational studies(1-9). Results 
from a meta-analysis of observational studies showed a 50% and 70% reduction in HIV 
risk amongst circumcised men from the general population and higher-risk groups, 
respectively(6). The most compelling evidence comes from three recent unblinded 
randomised control trials(RCT) conducted among adult men in Kenya, Uganda and South 
Africa(10-12) which suggested a 50% to 60% reduction in HIV risk among circumcised 
men across the three trials(Table 1). 
 
Given the overwhelming evidence and the limited preventive options available, 
WHO/UNAIDS have published recommendations for countries to consider scaling up 
access to MC in seronegative men, in areas of high HIV prevalence where MC is 
rare(13). However, a number of important issues such as the safety, cost, feasibility, 
acceptability, ethics, and potential increase in risky behaviour following circumcision 
should be considered ideally before the large scale implementation of MC(13). A better 
understanding of the potential population-level impact of MC is needed in order to 
identify who should be circumcised. Further research is needed to guide programme 
implementation and to better understand additional benefits or risks of MC, including the 
protective effects of MC on other sexually transmitted infections(STIs)(13). Without 
conducting community based randomised trials, the impact of circumcision at the 
population-level can be addressed with mathematical modelling if we have a clear 
understanding of the protective biological mechanisms of MC at the individual-level. To 
achieve this, it is useful to clearly understand the results of the circumcision trials and to 
make a distinction between efficacy and effectiveness of MC. 
 
In this paper, we first review and discuss the efficacy and effectiveness of MC on HIV, in 
particular the incremental benefit of MC on HIV infection due to its indirect protection 
against cofactor STIs in the context of the three aforementioned randomised trials(10-12). 
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In addition, we present new results on the incremental benefit of MC at the population-
level due to its efficacy against other STIs.  
 
Methods 
 
The population-level impact of MC on HIV prevalence was assessed using a previously 
validated stochastic compartmental model which simulates transmission of HIV and one 
STI in the heterosexual population in the Kisumu district of Kenya(12,14). The modelled 
population was stratified into six sexual activity classes with specific rates of sexual 
partner acquisition. In absence of specific data, the mixing between activity classes was 
assumed to be proportionate. The STI was modelled with two compartments representing 
infected or not infected individuals. Infecteds could recover from the STI and be 
reinfected. Without loss of generalisability, the modelled STI should be thought of as 
‘generic’, rather than representing any one specific STI. HIV infection has been modelled 
with 5 stages representing susceptible, acute, asymptomatic, pre-AIDS, AIDS. The 
progression of individuals between states was based on specific disease stage parameters 
or on the force of infection(for susceptible), which  depended on the sexual activity, the 
HIV or STI infection status, HIV and STI prevalence in the pool of partners, the strength 
of the HIV-STI interaction and the efficacies of MC against HIV(ES
HIV
) and STI(ES
STI
). 
Upon commencement of the circumcision intervention, a fixed number of susceptible 
men were recruited from the uncircumcised to the circumcised susceptible compartment. 
The model structure, the equations and the Monte-Carlo simulation process are fully 
described in Supplement material.  
 
High(scenario A) and low(scenario B) STI prevalence scenarios were modelled. The 
distribution by sexual activity classes and   rates of sexual partner acquisition for scenario 
B were selected to agree with infection rates in the Kisumu UNIM male circumcision 
trial population(12,14-17) and the 2003 Kenyan Demographic and Health Survey(15) 
corresponding to years 15-17 of the simulated epidemic. Remaining parameters for 
HIV(14,18-23) and STI(27-29) transmission probabilities, duration of the different HIV 
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states(14,18-24-26) and duration of STI infection(27-29) were based on published 
studies(Table 2).  
 
The presence of STI in the HIV-infected sexual partner was assumed to increase HIV 
per-partner infectivity by 4-fold, while STI in the HIV-susceptible increased per- HIV 
susceptibility by 3-fold. This reflected the results from a meta-analytic review of 
observational studies where the relative risk of HIV due to STI(RRs) in men was less than 
4.4 for genital ulcer disease(GUD), 3.1 for all STIs, 2.7 for herpes, 2.5 for syphilis, 3.9 
for gonorrhoea and 0.8 for Chlamydia(30-33). HIV infection was also assumed to 
increase susceptibility to and infectivity with STI by 1.5-fold(30-32). Scenario A was 
obtained from scenario B by increasing the average duration of STI infection from 6 
months to 1.3 years. Because this change also increased HIV infection rates, due to the 
STI and HIV interaction, we simultaneously decreased HIV transmission probabilities 
during the early stage and slightly modified the rates of sexual partner change in order to 
hold HIV infection rates to reasonable levels. The parameter values used for both 
scenarios and the key characteristics of the simulated STI and HIV epidemics are 
summarised in Table 2. In both scenarios, the male HIV prevalence was 28% at year 15 
and declined as the epidemic progressed due to a strong dependence on STI prevalence 
which declined due to AIDS differential mortality. In scenario A, the overall STI and 
HIV prevalence, and HIV incidence averaged 22.3%, 29.8%, and 5.9 per 100 person-
years over the 20 years following the intervention (introduced at year 15), respectively 
compared to 3.7%, 16.4% and 1.9 per 100 person-years respectively for scenario B(1-
3,12,14-17). 
 
To assess the individual-level impact of MC, Desai et al(14) simulated the Kisumu MC 
trial by recruiting and following-up 2750 initially uncircumcised seronegative men from 
the overall simulated population and randomly assigning them to the circumcision or 
control arm. The simulated follow-up was 24 months, HIV incidence rate was 2.5% per 
year in control subjects, STI prevalence averaged 8.2% in controls over the 2 years, 
which compares with the overall prevalence of bacterial infections observed in the UNIM 
trial participants at baseline. 
 9 
 
To assess the population-level impact of MC, new simulations were performed where a 
large scale mass circumcision programme was initiated in a mature HIV epidemic in low 
and high STI prevalence settings(scenarios A and B). Low to high values of MC efficacy 
against STI (6 scenarios in all) were assumed in MC interventions offered to 75% of HIV 
susceptible males(either STI positive or STI negative) instead of offering it to a minority 
of men (as in the simulated trials) where coverage was too small to generate herd 
immunity.  
  
Theoretical context  
Individual-level effect of MC: Efficacy vs Effectiveness 
 
In the clinical trial literature, “efficacy” is typically defined as the individual-level 
clinical/biological benefit of the intervention used under ideal conditions(e.g. with 100% 
compliance and adherence) – reflecting the maximal effect it can have. Individual-level 
“effectiveness”, often termed ‘real world’ effectiveness, (not to be confounded with the 
population-level effectiveness) refers to the effect of the intervention achieved under 
more realistic conditions of use(e.g., imperfect adherence) and relates more closely to the 
potential benefit of the intervention to individuals when widely used in practice(33-34).  
 
Determining the efficacy of MC is more complex because MC can have different 
individual-level efficacies, reflecting different biological/clinical protective mechanisms 
conferred to individuals directly against HIV or indirectly against other STIs(14,34), such 
as:  
(i) Reduction in susceptibility to HIV infection(Es
HIV
) or to other cofactors 
STI(Es
STI
); 
(ii) Reduction of the infectiousness of HIV infected(EI
HIV
) or STI infected(EI
STI
) 
circumcised men for their sexual partners;  
(iii) Modification of the natural history of STI infection by reducing the frequency of 
ulcers or by accelerating the natural clearance(Enh
STI
).  
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In RCTs, where HIV negative individuals are randomized and follow-up, it is only 
possible to estimate a reduction in acquisition to HIV(Es
HIV
 ) and STIs(Es
STI 
) 
independently(34).  
 
Because cofactors STI were on the causal pathway to HIV infection, the primary outcome 
of the three circumcision trials was the overall effectiveness of MC on HIV acquisition, 
rather than the independent efficacies against HIV and STIs(11). Thus, the overall 
effectiveness(i.e. the overall reduction in HIV incidence) measured in the trials could 
have been the result of a combination of direct protection(efficacies) against HIV 
acquisition(Es
HIV
) and/or against acquisition of cofactor STI(Es
STI
). For example, in the 
South African MC trial, the overall effectiveness of 60% could be due to an efficacy 
against HIV only (Es
HIV
=60%,Es
STI
 = 0%) or to some degree of protection against both 
HIV and STI(0%<Es
HIV
<60%,0%<Es
STI
 < 60%).  
 
Population-level and long term: impact 
 
MC has direct effects on HIV at the individual-level and additional indirect effects at the 
population-level due to herd immunity(i.e a reduced exposure to infection among non 
circumcised men or women due reduced STIs or HIV prevalence)(31). The total 
population-level impact is function of the different individual-level efficacies(Es
HIV
,Es
STI 
,EI
HIV
,EI
STI
,Enh
STI
), thus justifying the need to quantify each of them when possible. 
 
It is also important to evaluate the incremental role played by MC on reducing the 
incidence of new STI infections and indirectly preventing new HIV infections. 
Knowledge of Es
HIV
 and Es
STI
 can help interpret the MC effectiveness results on HIV and 
to extrapolate results to other communities. If most of the protection against HIV was 
obtained indirectly via the protection against STIs, then the trial results would depend 
more strongly on the epidemiology of STIs and the trial population and would therefore 
have a poorer external validity. The potential impact of MC at the population-level would 
also depend on the prevalence of the different STIs and the associated synergetic impact 
with HIV.  
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Biologically, MC may reduce susceptibility to HIV infection because the underside of the 
foreskin is rich in HIV target cells(CD4+ T cells). It may also reduce the risk of abrasion, 
micro tearing and inflammatory conditions suffered by the inner mucosa of the foreskin 
in uncircumcised men(10-13,35-36). Only one observational study in Rakai suggested a 
reduction in infectiousness of HIV positive circumcised men for their female partners(8). 
However, in a very recent clinical trial in Rakai, higher(but not statistically significant) 
HIV incidence was observed among the wives of circumcised HIV positive men, which 
was attributed  to premature resumption of sexual activity following the surgical 
procedure, rather than behavioural disinhibition(37).The protective effect of MC against 
STIs is more uncertain(37-45). A meta-analysis suggested a 33% and 12% reduction in 
the risk of syphilis and HSV-2 among circumcised men, respectively(38). The estimates 
across different observational studies varied between -10% to 88% for chancroid. 
Evidence on the protective effect against gonorrhoea is unclear and mostly based on early 
studies(9,39,41-44). One study suggested a reduced rate of Chlamydia transmission to 
their female partners by circumcised compared to uncircumcised men(45). Thus, in the 
results presented below, the MC efficacies were modelled as a reduction in males’ 
susceptibility to HIV infection which was fixed to 60%(Es
HIV
). The efficacy against 
STI(Es
STI
) was varied between 0% and 70%. Low Es
STI
(~0-20%) reflected the efficacy of 
MC on chlamydia and HSV-2 while high Es
STI
(~60-80%) reflects efficacy against 
chancroid and syphilis(11,38,40). We assumed that male-to-female HIV transmission was 
unchanged by circumcision status(Table 2).  
 
Results 
Insights from previous clinical trial simulations 
 
The protective role of MC against cofactor STI on the risk of HIV infection at the 
individual-level was assessed in Desai et al(14 study, where a small fraction of men were 
follow-up for two years in the simulated UNIM MC trial in Kisumu(Table 1).  Under the 
UNIM simulated conditions, if MC did not protect against HIV(Es
HIV
=0%) but strongly 
protected circumcised men (HIV+ or  HIV-) against the STI only(Es
STI
=80%), the overall 
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effectiveness against HIV would be only 13%. If the trial duration was prolonged to 5 
years and MC efficacy against STI was increased to 100%, the overall effectiveness 
against HIV, due to the protection against STI alone, increased to 21%.  The 
effectiveness reached 25% or 30% only when the STI prevalence was increased to 19% 
or when the RRS was increased to six-fold respectively. As these assumptions, especially 
the 100% efficacy against the STI appeared unrealistically high, the authors concluded 
that the effectiveness above 50%, as observed in the field RCT, could not have been due 
solely to the protection against cofactor STI. MC needed to strongly protect directly 
against HIV(14).  In addition, under the  STI conditions, MC needed to have an HIV 
efficacy of at least 40% and 50% to generate the observed overall effectiveness of 50% or 
60% against HIV, respectively, even if the efficacy against STI was as high as 60%(14). 
This also meant that if the MC efficacy against HIV was 40%, not more than 20% of the 
HIV infections prevented in the circumcised arm of the trial could be attributable to the 
efficacy against the STI(rather than efficacy against HIV). This proportion decreased as 
the efficacy against HIV increased(Figure 1A).  
 
Insight from the three MC circumcision trials 
 
The effect of circumcision on STI incidence was not reported in the South African 
trial(10). The baseline STI prevalence only was reported in the Kenyan trial. Gray et 
al(11) reported a baseline prevalence of 7% and a 47%(95% CI: 36%-57%) reduction in 
self-reported GUD in the circumcised arm during part of the trial(Table 1). In subgroup 
analysis, an effectiveness of 40%(95% CI: 8%, 66%) against HIV was reported in the 
GUD negative group compared to an effectiveness of 51%(95% CI: 16%, 72%) for the 
whole cohort. In line with the meta-analysis results for high-risk individuals(6), the Rakai 
sub-group analyses reported an effectiveness of 71%(95% CI -29%, 97%) and 70%(95% 
CI: 15%, 91%) in men reporting more than 2 partners and with self-reported GUD, 
respectively. Based on our simulation results, the difference between an effectiveness of 
70% and an effectiveness of 50%-60% among high-risk individuals compared to general 
population, respectively, could partly be explained by the additional protection of MC 
against STIs if the STI prevalence(>>20%) or the recurrence of ulcers among high-risk 
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individuals is high. In addition, under the UNIM trial conditions, MC efficacy against 
HIV is predicted to be at least 40%-50% given that the observed individual-level MC 
effectiveness in the three trials was 50%-60%.  
 
Insights from new simulation results: Population-level and long term impact 
 
Because the trials were of short duration and only captured the reduction in susceptibility 
to HIV infection(at the individual-level), the field and the simulated trials do not 
necessarily reflect adequately the incremental impact of MC on HIV at the population-
level due to its protective impact against cofactors STI. The full incremental impact due 
to MC efficacy against STIs may be larger at the population-level and over a longer time 
scale when coverage increases. To understand the extent of the impact of MC efficacy 
against STI, we simulated a high(A) and low(B) STI scenario, with a strong STI-HIV 
interaction.   
 
Figure 1B shows the impact of MC on HIV prevalence over time for scenario A. The 
figure shows that MC can reduce the long term male HIV prevalence and that females 
would somewhat benefit from herd immunity effect but not noticeably until five to ten 
years following the intervention. Importantly, the figure also highlights the small 
incremental impact of MC due to MC efficacy against STI in the long term, even if Es
STI
 
was as high as 70% and if STI prevalence was high. The incremental benefit of MC Es
STI
 
was slightly greater for women than men because STI prevalence declines faster than 
HIV prevalence in men, and females benefit from the reduced HIV infectivity of men 
who avoid STIs. Figure 2 summarises the percentage reduction in HIV prevalence 5 and 
15 years after the introduction the circumcision intervention.  MC efficacy against the 
STI has a limited impact even in the long term, unless STI prevalence is high (scenario 
A) and Es
STI
 is higher (>70%) than currently suggested by data. In the long term, females 
could benefit substantially from the herd immunity effect of MC (20% reduction in HIV 
prevalence).  Even at the population-level, MC efficacy against HIV produced most of 
the benefit on HIV in both men and women. Only under specific conditions of very high 
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STI prevalence, high synergetic interaction or large Es
STI
, could MC efficacy against STI 
produce a noticeable incremental benefit for men and women. 
 
Discussion 
 
In this paper, we distinguished between the overall effectiveness of MC and the efficacies 
of MC against HIV and STIs in order to assess the population-level impact of MC on 
HIV. Together, the field and simulated trial results suggested that only a small fraction of 
the observed MC effectiveness against HIV in the RCT could be due to the indirect 
efficacy against STIs, rather than the efficacy against HIV. The fact that Es
STI
 contributed 
little to the overall individual-level effectiveness, may explain the consistency of the 
estimates, which varied by less than 10% across trials, despite differences in STI 
prevalence. Thus, the three circumcision trials have good external validity and the results 
can be extrapolated to settings with different STI epidemiology. To generalise trial 
results, to settings outside sub-Saharan Africa, the mechanism of protection against HIV- 
in particular the relative role of hygiene compared to biological mechanisms - remains to 
be clarified.  
 
Our results support previous modelling studies suggesting that MC has the potential to 
help curb the HIV epidemic in the long term, in population where MC prevalence is low 
and in absence of associated sexual disinhibition(46-51). If enough men are circumcised, 
females will benefit from long-term herd immunity effects.  In our model, men were 
circumcised in a short window period. In practice such high coverage would be reached 
over a longer term period. It is therefore important to determine who should be 
circumcised first(e.g., younger and more sexually active men) in order to scale-up 
circumcision programme to achieve maximum impact very rapidly(51). The population-
level impact of MC would even be larger, especially for females if it also reduced the 
infectiousness of HIV positive circumcised men. However, it could also have detrimental 
effects if men were more infectious to their female partners immediately after the 
procedure(37,46).  This has obvious implications for the roll-out of mass circumcision. 
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In the long term, our analysis suggested that the incremental population-level impact of 
MC on HIV due to a reduction in the acquisition of STIs(Es
STI
) among male is also likely 
to be small. Although we only modelled one generic STI, our conclusions remained valid 
under extreme assumptions of high MC efficacy against STI (higher than what has been 
observed), strong STI and HIV association, and very high STI prevalence(Figure 2). The 
incremental benefit of Es
STI
 was marginally better for women than men simply because 
their protection was mediated by herd immunity effects through the rapid decline in STI 
prevalence among men. Based on current knowledge, we assumed that MC reduced 
acquisition of new STIs. However, if MC also reduced the frequency or duration of ulcers 
during the course of infection(11,40), this may provide additional incremental benefits. 
Considerable uncertainty remains regarding MC efficacy against STIs.  The Rakai 
circumcision trial on HIV acquisition reported a 50% reduction on self-reported 
GUD(40). However, results from a complementary trial observed a 25% reduction in 
acquisition of HSV-2 among HIV negative circumcised male, and a 25% reduction in 
GUD(40). These estimates of MC efficacy against HSV-2 were greater than those 
suggested in Weiss’s meta-analysis(35,38). The incremental effect of MC on HIV among 
females would be larger if MC also reduces bacterial vaginosis and trichomonias in the 
wives of circumcised men(40). 
 
Our results do not demonstrate that MC does not protect against STIs. They only predict 
that the incremental impact of MC against HIV due to a reduction in males’ 
susceptibility(Es
STI
) to STI is likely to be relatively small in generalized HIV epidemics. 
Additional work is needed to identify if MC efficacy against STIs can produce more 
significant benefits under different epidemic characteristics(e.g. concentrated, rising) and 
to better understand how MC protect against STIs. Even if MC efficacy against STIs did 
not play an important role in preventing HIV, it would still be beneficial to reduce the 
burden of STIs. 
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Figure legend: 
Figure 1 
A: Individual-level effectiveness: Fraction of new HIV infections prevented over 2-yers 
follow-up in the circumcised arm of the simulated Kisumu trial that is due to the indirect 
protection of male circumcision(MC) against the STI, rather than to a direct protection 
against HIV(y-axis). In these simulations, both Es
STI
 and Es
HIV
 were varied. The 
maximum HIV infection prevented is 100%. Thus, is the STI efficacy(Es
STI
) component 
prevented 20% of new infections, the remaining 80% prevented was due to the efficacy 
against HIV(Es
HIV
). As Es
HIV
 , the contribution of Es
STI
  to the total infections prevented 
declined.  
 
B: Population-level effectiveness: Overall male and female HIV prevalence over time 
without and with the circumcision intervention in scenario A when Es
HIV 
=60% and Es
STI
 
varied from 0% to 70%. 75% of uninfected men are reached and circumcised at the 
beginning of the intervention introduced in a mature epidemic. Scenario A: STI 
prevalence averaged 24.3% and 20.2% in female and male, respectively. 
 
Figure 2: Percentage reduction in overall male and female HIV prevalence between an 
uncircumcised and circumcised population A) 5 and B) 15 years after a circumcision 
intervention. 75% of uninfected men are reached and circumcised at the beginning of the 
intervention which is delivered 15 years after the beginning of the HIV epidemic in 
scenario A and B . Scenario A: STI prevalence averaged 24.3% and 20.2% in female and 
male, respectively. Scenario B: STI prevalence averaged 2.9% and 4.5% in female and 
male, respectively. 
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Table 1: Summary of the three randomised circumcision control trials 
 South Africa 
(Orange Farm, Gauteng) 
Auvert et al(2005) 
Uganda 
(Rakai) 
Gray et al(2007) 
Kenya 
(Kisumu) 
Bailey et al(2007) 
Community Characteristics 
Population Semi-urban Rural Urban 
MC rate 20% 16% 10% 
HIV incidence(per year) ~1.7% ~1.8% ~1.8% 
Study Characteristics 
Age 18-24 15-49 18-24 
Sample size 3274 4996 2784 
Mean follow-up 18 months < 24 months 24 months
1
 
Overall effectiveness 
(Intention-to-treat) 
60% 
95%CI=32-76% 
51% 
95%CI= 16-72% 
53% 
95%CI=22-72% 
STI- at baseline NR 
-Patients with potential GUD 
were excluded until 
successful treatment 
 
 
-Self reported: 
7% GUD, 3.5% urethral 
discharge, 6% Dysuria 
-Patients with potential 
GUD were excluded until 
successful treatment 
 
 
28% HSV-2, 1% 
Syphilis, 2% 
Trichomonas 
vaginalis, 2% 
gonorrhoeae, 5% 
chlamydia, 0% 
Heamophilus 
ducreyi 
-Patients with STI 
were deferred until 
treatment 
Protection of male 
circumcision against STI 
-The proportion of 
participants attending a clinic 
for a GU problem in the 12 
months prior to the visit at 
month 12 was 4.7% in the 
intervention group compared 
to the control group(7.2%). 
Self-reported STI: 
GUD: 47%(36%-57%) 
Genital discharge: 16%(-
11%, 37%) 
Dysuria: 3%(-21%-23%) 
 
NR 
 
Protection of male 
circumcision against HIV 
after controlling for 
acquisition of other STI 
during the trial 
NR No GUD: 40% 95%CI=-
8%-67% 
Self reported GUD: 71%(-
29%-97%) 
NR 
 
 These trials were not designed to provide evidence on the potential mechanisms 
of protection of male circumcision on HIV acquisition 
NR: Not Reported, 
1
median 
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Figure 1 
A)  
Fraction of HIV infections prevented in the circumcised arm 
due to the indirect protection of MC against cofactor STI over a 2 year trial 
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Figure 2: 
A) 
Population-level impact 
at 5 years post intervention
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B) 
Population-level impact 
at 15 years post intervention
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Table 2: Parameter input values used in model simulations for the low baseline (B) and high (A) STI prevalence scenarios (additional 
model details are provided in supplement material) 
Description of epidemiological parameters  Parameter value with Symbols
1
 Reference
s 
Duration of HIV stages: 
11  = 4.4 months, stage 2: 21  =6.5 yrs, stage 3: 31  = 2 yrs. 
14,18,24-
26 
h
ijk ,*, : HIV transmission probabilities per partnership 
from individual of sex k*, sexual activity class j and infection phase h(h=2,3,4) to partner 
of opposite sex k and class i. Values for females(k*=1) of low activity class(j= 1,2 = 
lowf) or high activity class(j=3,...,6 = highf) to males of low activity class(i= 1,2 = 
lowm) or high activity class(i=3,...,6 = highm). Transmission probabilities for male to 
female are doubled. 
Scenario A 14, 18-23 
015.0
015.0
026.0
048.0
2
,,1
2
,,1
2
,,1
2
,,1




highmhighf
lowmhighf
highmlowf
lowmlowf




 
001.0
001.0
0017.0
0032.0
3
,,1
3
,,1
3
,,1
3
,,1




highmhighf
lowmhighf
highmlowf
lowmlowf




 
0071.0
0071.0
026.0
051.0
4
,,1
4
,,1
4
,,1
4
,,1




highmhighf
lowmhighf
highmlowf
lowmlowf




 
Scenario B 
015.0
015.0
026.0
048.0
2
,,1
2
,,1
2
,,1
2
,,1




highmhighf
lowmhighf
highmlowf
lowmlowf




 
001.0
001.0
0017.0
0032.0
3
,,1
3
,,1
3
,,1
3
,,1




highmhighf
lowmhighf
highmlowf
lowmlowf




 
0071.0
0071.0
026.0
051.0
4
,,1
4
,,1
4
,,1
4
,,1




highmhighf
lowmhighf
highmlowf
lowmlowf




 
Duration with STI infection for all sexes k and activity classes i.   Scenario B: ,1 k i = 6 months  Scenario A:  ,1 k i =1.33 years 
27-29 
Per partnership STI transmission probability: 
from infected individual of sex k and sexual activity class j to partner of opposite sex k* 
and class i. 
, ,k i j = 0.15 for all k,i,j 
 27-29 
HIV cofactors: relative risk(multiplicative factor) for: 
a1 = increased infectivity with HIV given partner co-infected with STI; a2 = increased 
susceptibility to HIV given STI infection in the self  
a1 = 4 
a2 = 3 
 
 
 
 
30-32 
STI cofactors: relative risk(multiplicative factor) for:  
b1= increased infectivity with STI given partner co-infected with HIV; b2= increased 
 b1=1.5  
 b2 =1.5 
 
 
 
 27 
susceptibility to STI given HIV infection in the self. 
Mortality rate due to AIDS (α) 1

= 1 year 
 24-26 
Annual rate of sexual partner change: 
m k,i is the number of new sexual partners per year for person of sex k and sexual activity 
class i. k=1 represents females; k=2 males. 
Scenario B: 
m k=1,i=1…6  =  
1.0  3.5    5 10 50 75 
m k=2,i=1…6 =  
1.5  5.0  10 15 20 25  
Scenario A: 
m k=1,i=1…6  =  
1.5  4.0  6 12 35 40 
m k=2,i=1…6 =  
1.0  3.5  5 10 25 35 
Assumed 
Percentage of population by activity class i for class k at start of HIV epidemic: ppk,I 
(%) 
pp k=1, =1…6= 55 20 10 10   2.5 2.5  
pp k=2, =1…6= 50 30   5   5   5    5 
 
 
Assumed 
Rate of departure from sexually active population  = 0.029 (1  = 35 yrs)  Assumed 
Size of population     100 000   Assumed 
Coverage =Percentage of HIV-negative males recruited for circumcision     75%  Assumed 
Efficacy of circumcision against HIV Es
HIV
 = 60%  10-13 
Efficacy of circumcision against STI Es
STI
 = 0%, 40%, 70%  11,37-45 
Model output   
Average HIV prevalence in general population over 20 yers Scenario A: 29.8% Scenario B: 16.4% 1-3,12,14-
17 Average STI prevalence in general population over 20 years Scenario A: 22.3% Scenario B: 3.7% 
Average HIV incidence in general population over 20 years Scenario A: 5.9 per 100 person-years Scenario B: 1.9/100 p-yr 
1
 Symbols relate to equations in Appendix 
 
 
 
